Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

EIGR Eiger BioPharmaceuticals Inc

0.00 (0.00%)
Apr 11 2024 - Closed
Delayed by 15 minutes


Draw Mode:

Volume 0
Bid Price 1.72
Ask Price 1.73
News -
Day High


52 Week Range


Day Low
Company Name Stock Ticker Symbol Market Type
Eiger BioPharmaceuticals Inc EIGR NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 1.725 20:00:00
Open Price Low Price High Price Close Price Prev Close
1.725 1.725
Trades Volume Avg Volume 52 Week Range
0 0 - 1.10 - 43.35
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 1.725 USD

Eiger BioPharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
2.54M 1.48M - 13.48M -96.78M -65.41 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Eiger BioPharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No EIGR Message Board. Create One! See More Posts on EIGR Message Board See More Message Board Posts

Historical EIGR Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.482.59771.662.08169,110-0.755-30.44%
1 Month5.497.201.101.90370,584-3.77-68.58%
3 Months7.108.26721.102.09122,221-5.38-75.70%
6 Months8.40314.3371.106.51212,735-6.68-79.47%
1 Year27.6043.351.1017.40304,216-25.88-93.75%
3 Years250.80300.6391.10121.94428,978-249.08-99.31%
5 Years431.40474.601.10184.15381,616-429.68-99.60%

Eiger BioPharmaceuticals Description

Eiger BioPharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria, and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.

Your Recent History

Delayed Upgrade Clock